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Abstract 
There has been increasing recognition that the alarming surge in allergy and 
autoimmunity in the industrialised and developing worlds, shadows the rapid 
eradication of pathogens, such as parasitic helminths. Appreciation of this has 
fuelled an explosion in research investigating the therapeutic potential of these 
worms. This review considers the current state-of-play with a particular focus on 
exciting recent advances in the identification of potential novel targets for 
immunomodulation that can be exploited therapeutically. Furthermore, we 
contemplate the prospects for designing worm-derived immunotherapies for an ever-
widening range of inflammatory diseases, including, for example, obesity, 
cardiovascular disease and ageing as well as brain developmental disorders like 
autism.  
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Worms really may be good for you, after all  
An evolutionary viewpoint of the development, regulation and function of the immune 
system is gaining increasing traction. This reflects awareness that, in addition to 
shaping metabolism and the function of major organs [1, 2], co-evolution with 
commensal and environmental microbes and “Old Friend” infections has generated a 
mammalian immune system that optimises the symbiotic survival of bacteria, fungi, 
latent viruses and parasites (macrobiota), whilst minimising pathological 
consequences for the host [3-6].  Specifically, exposure to such persistent, tolerated 
infections rather than the more recently evolved “crowd infections” (e.g. childhood 
viruses, like measles) that diametrically either kill or induce protective immunity, 
appears to be required early in life for induction of the regulatory networks that 
prevent autoimmunity and allergic inflammatory responses to harmless agents, and 
also for the homeostatic resolution of infection-fighting inflammation, once the 
pathogen is cleared [3-6]. Recognition of this balanced education of the immune 
system has revolutionised our understanding of how its dysregulation provides a 
unifying mechanism for the development of allergic and autoimmune inflammatory 
disorders, metabolic syndrome, and the chronic low-grade inflammation that 
characterises ageing. The alarming rise in each of these appears to shadow the 
dysbiosis of the macrobiota resulting from the sudden and swift eradication of 
organisms like helminths in rapidly developing societies (Fig. 1). Likewise, it 
accounts for the epidemiological evidence that, rather than protect against allergic 
and autoimmune inflammatory disorders, ‘crowd infections’ may even trigger them, 
reconciling findings that previously were perceived as flaws in the Hygiene 
Hypothesis [3]. 
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Despite the fact that “therapeutic” infection with parasitic worms may not always 
result in improved clinical outcome and may even exacerbate the target pathology 
[7], there has been intense focus on exploiting the immunoregulatory actions of 
helminths to develop novel therapies to treat disease. Extensive studies (reviewed 
[8-10]) have strongly evidenced the potential of worm therapy in animal models and 
although less consistent, particularly with respect to allergic responses, this has 
been supported by epidemiological data from endemic regions. Indeed, there are 
striking inverse incidences between infection with filarial nematode worms and both 
rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) [11-13], as well 
as a lower prevalence of filarial infection in type 2 diabetes patients, in India. 
Likewise, lower body mass index and fasting blood glucose levels have been 
reported in those with a history of schistosomiasis in rural China [14]. Further support 
is provided by health initiatives such as deworming being associated with increases 
in the prevalence of atopy in endemic areas, an outcome that is now questioning the 
wisdom of current mass eradication programmes [10]. Collectively, these 
observations have driven clinical trials of therapeutic infection with pig whipworm 
(Trichuris suis) and human hookworm (Necator americanus) in a range of allergic 
and autoimmune inflammatory diseases as well as autism (reviewed in [9]). 
However, despite the reported success of helminth self-infection in combating 
inflammatory bowel diseases (IBD) like ulcerative colitis [15] and other autoimmune 
and allergic inflammatory disorders and their neuropsychiatric comorbidities such as 
anxiety and autism [16],  the ability of worm therapy to consistently improve clinical 
outcome, apart from some promising results in coeliac disease [17, 18], remains 
disappointingly unproven to date [9, 10, 19]. Nevertheless, and because it is not 
ideal that patients are treated with live pathogens, great strides have been made in 
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recent years in identifying the roles and targets of molecules excreted-secreted (ES) 
by helminths (secretome; [20-23]) to modulate the immune response and promote 
tissue repair (Box 1): this raises the exciting possibility that ES can potentially be 
exploited as biologics and/or form the basis for the development of small molecule 
drugs [19-26].   We shall therefore discuss the current focus areas of helminth-based 
therapy that are advancing our understanding of development of the immune 
response and its dysfunction in disease, concentrating on the identification of novel 
and safe targets of potential therapeutic intervention.  
 
Infection with parasitic worms helps identify key immunoregulatory 
mechanisms  
Type 2 (Th2) immune responses are induced to clear parasitic helminth infections, 
but the worms have evolved a variety of mechanisms to elicit regulatory responses 
that promote their survival and counter the Th1/Th17-mediated pathology that would 
likely arise in the absence of such a modified Th2 response [8]. These regulatory 
responses notably involve regulatory B- and T-cells and macrophages (often termed 
M2 or alternatively-activated [AAM] macrophages) and the production of a range of 
cytokines, particularly IL-10, IL-35 and TGF-β, and AAM products like RELMα, 
Arginase and Ym1 [27]. Such regulatory responses have the serendipitous side-
effect of also alleviating aberrant inflammation irrespective of its phenotype, 
explaining the ability of helminths to target both Th2-driven allergic and Th1/Th17-
driven autoimmune inflammation [8]. 
 
In addition to highlighting their therapeutic potential, studies investigating 
immunomodulation by helminths have identified and validated key regulators of 
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disease pathogenesis. For example, regulatory T cell responses (Treg, Tr1 and 
iTR35 cells) are induced to limit inflammation in chronic helminth infection [8, 28] and  
protection against allergic and autoimmune disease by helminths is increasingly 
recognised as involving the mobilisation of a variety of regulatory B cells (Bregs) 
which, in some cases, appear responsible for consequent induction of protective 
regulatory T cell responses [29-32]. Thus, in models of acute asthma, whilst transfer 
of splenic and lung-derived Marginal Zone (MZ)-like Breg populations, induced upon 
infection with Schistosoma mansoni, conferred protection against ovalbumin (OVA)-
induced airway hyper-responsiveness (AHR) in an IL-10-dependent but Treg-
independent manner [29], a splenic T2-MZP subset of Bregs afforded protection in 
an IL-10- and regulatory T cell-dependent manner [29-31].  Likewise, a CD19+CD23hi 
population of B cells induced by Heligmosomoides polygyrus reduced development 
of house dust mite (HDM)-induced airway inflammation and also experimental 
autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS) in mice. 
However, in the case of EAE, protection did not appear to be dependent on IL-10 
production by such B cells [33], despite this being the case for MS patients in 
endemic areas [32, 34].  
 
More recently, the use of helminth infection models has identified novel roles for 
eosinophils and basophils [35-37] in regulating Th2-, innate lymphoid cell (ILC)-, and 
AMM-mediated immunity and thus in fighting infection, maintaining metabolic 
homeostasis in adipose tissue and promoting tissue repair [38-40]. Moreover, these 
models have highlighted the role of tuft cells, specialised epithelial cells that are 
found in low numbers in healthy gut tissue but are expanded in response to a range 
of helminth infections and initiate ILC-2-mediated inflammatory and goblet cell 
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responses that promote worm expulsion [41-43]. Similar epithelial effects may also 
pertain in the lungs [43, 44], where ILC2 cells are recruited not only to mediate 
helminth-induced lung inflammation [45] but also to promote tissue repair [46]. 
Furthermore, IL-22 which can be produced by ILC3s to inhibit systemic inflammation 
by combating bacterial infection and promoting gut barrier integrity [47], similarly 
promotes expulsion of both Nippostrongylus brasiliensis and Trichuris muris by 
stimulating goblet cell responses [48].  Such IL-22-driven effects are reminiscent of 
those observed in protection against ulcerative colitis following self-infection with 
Trichuris trichiura where the accumulation of Th22 cells in the mucosa was also 
associated with goblet cell hyperplasia and mucus production [15].  
 
Collectively these recent studies investigating immune responses to helminths have 
advanced our fundamental understanding of the molecular and cellular mechanisms 
underpinning type-2 immunity and have highlighted not only previously unsuspected 
interactions between cells of the innate and adaptive immune systems but also 
amongst these cells and their stromal environments (Fig. 2).   
 
Helminth-based therapies to reset immune homeostasis  
Although immunomodulation arising from helminth infection may be a result of the 
induction of regulatory T cell responses [8], the therapeutic effects of this may be a 
fortuitous consequence of bystander suppression. Consistent with this, although ES 
products can induce IL-10 regulatory responses [22], there is less evidence that they 
induce Tregs.  Nevertheless, ω1, an ES product from S. mansoni induces Tregs in 
NOD mice [49] and a TGFβ mimic in H. polygyrus ES was found to drive their 
differentiation in vitro [50]. However, none of the protection afforded by ES-62, a 
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particularly well-characterised secreted product of Acanthocheilonema viteae that 
protects against both allergic and autoimmune inflammation is achieved in this way 
[22, 25, 26]. Indeed, helminths or their products appear able to dampen inflammation 
in Th1/Th2/Th17-associated pathologies by modulating various distinct targets that 
may differ depending on the model investigated.  
 
Thus, an inflammatory disease-centric approach may have obscured an intrinsic 
mode of action of helminth ES products, namely to restore immune homeostasis 
irrespective of the phenotype of aberrant inflammation. This may explain the findings 
that ES-62 can both reinstate the Th1/Th2 balance away from Th2 in airway 
inflammation by inducing IFNγ whilst inhibiting Th1/Th17 responses in collagen-
induced arthritis (CIA)  [22, 25, 26]. However, ES-62 does not achieve the latter by 
invoking a compensatory induction of Th2 cytokines, but rather, by harnessing the 
inflammation-resolving, tissue repair properties of IL-22 in the arthritic joint [51, 52]. 
By contrast, ES-62 exhibits inverse effects on the IL-17/IL-22 inflammatory axis 
whilst preventing disease development in the MRL/Lpr mouse model of SLE [53].  
Rationalising this, whilst Th17 cells can act as master regulators of Th1 and Th2 
responses, IL-17 and IL-22 can exhibit dual pathogenic and inflammation-resolving 
properties even within the same disease model depending on the stage of pathology 
and inflammatory microenvironment [52, 53]. The homeostatic effects of ES-62 can 
also be explained in terms of its ability to reset inflammatory MyD88 signalling to 
normal levels and, in doing so, generate IL-10-producing Bregs that are associated 
with its protection against CIA, lupus-like nephritis and chronic airway inflammation 
and remodelling [53-55].  Consistent with this, transfer of splenic B cells from ES-62-
conditioned mice is sufficient to prevent development of autoantibody production and 
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pathogenic Th22 responses as well as reset the protective M2:M1 cell balance in the 
kidney in recipient lupus-prone mice [53]. Such a key role for MyD88 downregulation 
in preventing disease is supported by lineage-specific deficiency in the adaptor 
molecule being sufficient to abrogate lupus-like (B cells) [56, 57] and high fat diet 
(HFD)-induced cardiovascular (myeloid and endothelial cells) [58] pathologies in 
inflammatory mouse models. The mechanisms exploited by ES-62 remain to be fully 
delineated but involve the homeostatic induction of selective autophagy, which 
normally acts to limit TLR-driven inflammation, to degrade MyD88 and downstream 
effectors [59, 60].  
 
By contrast, Wmhsp60 of Wolbachia (an endosymbiont of many filarial nematode 
species), which inhibits autophagy via stimulating counter-regulatory mTOR 
signalling, drives TLR4-MyD88-mediated inflammation that results in a senescent, 
inflamm-ageing-like phenotype of monocytes [61]. Wolbachia appears to be 
important for embryogenesis, growth and survival of many filarial parasites and there 
is increasing evidence that the inflammatory responses it elicits contribute to the 
(potentially catastrophic) pathology resulting from parasite death and loss of helminth 
immunomodulation. As normal monocyte function can be restored and inflammation 
limited by the use of the mTOR inhibitor, rapamycin, these findings provide a 
potential breakthrough on how to prevent the severe adverse effects associated with 
anti-filarial chemotherapy [61].  
 
Helminth infections modulate the epigenetic landscape of inflammatory cells  
The macrobiota can shape immune responses by modulating hematopoiesis  
(“Trained Immunity”) via processes that can become dysfunctional in inflammatory 
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disease, cancer and ageing [62], with many of these defects in the regenerative 
potential of haemopoietic stem cells reflecting changes in their epigenetic landscape 
that are potentially therapeutically reversible. Interestingly, helminth induction of 
AAMs involves epigenetic modifications to drive the required transcriptional program 
[63]. Specifically, an H3K27 demethylase termed Jumonji domain containing-3 
(Jmjd3) has been shown to be essential for macrophage differentiation, activation 
and helminth-induced M2 polarisation [64].  Moreover, Histone Deacetylase-3 
(HDAC3)-deficient macrophages exhibit a phenotype similar to IL-4-induced AAMs 
[65] and consistent with this, pulmonary inflammation resulting from exposure to S. 
mansoni eggs, which is limited by AAMs, was found to be reduced in mice with 
HDAC3-deficient macrophages [63]. Further support that helminths and their 
products can impact on epigenetic regulation of macrophage responses was 
provided by the imprinting of M2 polarisation and associated IL-10 responses by T. 
suis soluble products being reversed by HDAC inhibitors that resulted in reduced 
histone acetylation of the TNF-α and IL-6 promoters [66]. Moreover, suppression of 
M1 responses in a Mesocestoides corti model of neurocysticercosis is associated 
with reductions in activating H3K4Me3 and H3K9/14Ac marks at the promoters of 
TNF−α, IL-6, NOS2, MHC-II and CIITA [67]. 
 
Helminths can likewise impact on DNA methylation and relating to this, S. mansoni 
infection drives induction of a functionally plastic population of CD4+ T cells that can 
be distinguished by its unique DNA methylation signature, relative to classical Th1 
and Th2 phenotypes [68].  Furthermore, studies exploiting dendritic cells (DCs) that 
lack the methyl-CpG-binding protein, Mbd2, showed that such cells were defective in 
their ability to induce Th2 responses to helminths and allergens and this was 
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associated with multiple changes in their transcriptional programme associated with 
H3K9/K14 acetylation marks and consequently, regulation of chromatin structure 
[69]. Intriguingly, analysis of priming of Th2 responses by skin DCs reflected 
induction of quite distinct transcriptional profiles in response to N. brasiliensis versus 
the contact sensitiser, dibutyl phthalate (DBP) as exemplified by a rather surprising 
type-I IFN signature induced by the helminth [70]. 
 
Given that epigenetic (i.e. reversible) modification of gene expression can be 
transgenerational [71], the effect of helminth infection during pregnancy is an area of 
interest.  Of note in the context of education of (neonate) immune responses and its 
dysfunction in inflammatory disease, chronic S. mansoni infection during pregnancy 
was reflected by reduced airway hyper-responsiveness in the children. This was 
associated with decreased polarisation towards Th2 responses in infants that 
corresponded with reduced levels of histone acetylation in the IL-4 promoter regions 
in naive T cells [72] suggesting that maternal infection may impact on induction of 
immunoregulatory networks and their pathogenic dysfunction during childhood by 
transgenerational changes to the epigenetic landscape of immune system cells.  
 
Targeting integrated inflammatory and metabolic pathways to increase health 
and life span 
Increasing evidence suggests that chronic low-grade inflammation (driven by IL-6, 
IL-1β, IL-18, TNFα) generated by the rapid eradication of “old friends” like helminths, 
allied to widespread adoption of a HFD and sedentary lifestyle, promotes the 
dsyregulation of (mTOR-regulated) metabolic pathways underpinning the ageing 
process as well as its comorbidities, T2D, obesity and cardiovascular disease 
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(metabolic syndrome). Thus, interest is beginning to focus on whether exploiting the 
anti-inflammatory and tissue repair properties of helminths can improve life-span or 
at least improve the well-being and health of our ageing populations. Evidence from 
diet-induced obesity and atherosclerosis models, as well as epidemiological studies 
of filarial infection and schistosomiasis, support the hypothesis that helminths can 
protect against metabolic syndrome [14, 26]. Such protection has been related to 
reduced type-1 inflammation and/or resetting of metabolism (e.g. improved glucose 
tolerance and insulin sensitivity, browning of adipose tissue), reflecting the roles of 
ILC2s, eosinophils and AAMs in supporting metabolic homeostasis in adipose tissue 
[37, 39, 40, 73, 74] and the upregulation of genes controlling glucose and lipid 
metabolism by STAT6 [75]. Moreover, as helminths can utilise blood lipids and 
glucose and alter lipid metabolism, in conjunction with the homeostatic effects of Th-
2 polarisation on metabolism, infection can lower blood cholesterol and increase 
insulin sensitivity to protect against obesity and associated cardiovascular disease 
[76]. 
 
Treatment with helminth-derived molecules can likewise protect against metabolic 
syndrome [26]. For example, schistosome soluble egg antigen (SEA) and LNFP111 
improved insulin sensitivity and reduced type-1 inflammation [77]. SEA also restored 
the type 2 response in adipose tissue through eosinophil recruitment [78] and 
consequent macrophage polarisation towards an M2 phenotype, and increased the 
numbers of IL-4+, IL-5+ and IL-13+ CD4+ T cells [79].  Likewise, schistosome egg-
derived ω1 improves metabolic status by stimulating the IL-33-mediated recruitment 
of ILC2s, eosinophils, and AAMs in the adipose tissue [80], whilst protection by 
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Litomosoides sigmodontis antigen (LsAg) also involves the recruitment of 
eosinophils [81].  
 
Some of these effects likely reflect the ability of helminths to directly target the key 
regulatory nodes, MyD88 and mTOR, that interact to integrate inflammatory and 
metabolic pathways. For example, recent studies suggest mTORC2 signalling 
appears essential and specific to AAM-M2 differentiation and its deficiency in 
macrophages renders mice incapable of clearing pulmonary infection with N. 
brasiliensis and prevents their ability to regulate metabolic control of thermogenesis 
[82]. Moreover, as mTOR and autophagy are counter-regulatory [60], this provides 
another point of potential intervention by helminths: consistent with its induction of 
autophagy to limit TLR-mediated inflammation, ES-62 suppresses activation of 
PI3K/AKT, upstream regulators of mTOR [59, 83], whilst Brugia malayi microfilariae 
inhibit the mTOR pathway and induce autophagy in human DCs [84]. However, the 
ability of helminths to induce autophagy is not always good news, as the chronic 
oxidative stress underpinning transformation in hepatocellular carcinoma by the fluke 
Dicrocoelium dendriticum is associated with induction of autophagic vesicles by its 
somatic antigens [85].  
 
Perhaps more directly pertinent to their ability to modulate host metabolism and 
immune responses, parasite-glycolytic enzymes can be secreted, either free-form or 
in exosomes. In addition, as with their mammalian counterparts, there is increasing 
recognition that they exhibit multifunctional properties, allowing them, when attached 
to the parasite surface to play roles in mediating adherence and invasion, as well as 
in modulating immune responses (reviewed in [86]). Thus, GAPDH from 
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Haemonchus contortus appears to have C3-binding activity, enolase from 
Steinernema glaseri suppresses immune responses in insects and glucose-6-
phosphate isomerase from Echinoccus multicularis is thought to promote 
angiogenesis around the metacestode and promote its development and acquisition 
of nutrients [86].  
 
Collectively, therefore, these findings suggest potential in exploiting helminth 
products to modulate host metabolism in the context of inflammation to improve 
health- and lifespan. 
 
The microbiome and therapy - it takes two to tango!    
Neonates and animals raised under germ-free (GF) conditions have an “incomplete” 
immune system that is somewhat Th2-polarised and exhibits reduced levels of B and 
T cells and also, gut-associated immune responses [87, 88]. “Education” of the full 
immune response requires instruction by particular components of the macrobiome 
with, broadly speaking, type 1 responses elicited by pathogenic bacteria, systemic 
commensal bacteria and viruses, type 2/regulatory phenotypes by helminths, 
Clostridiales and Bacteroides fragilis, and type 17 by segmented filamentous 
bacteria (SFB) and fungi [6, 87, 88]. This interdependence places increasing 
importance in analysing helminth-induced immunomodulation in the context of the 
larger macrobiome and co-infection status to determine how the resulting crosstalk 
balances induction of appropriate responses without pathology [18, 89]. For 
example, it has recently been reported that microbiota-induced Tregs express the 
nuclear hormone receptor RORγT and can therefore also differentiate into Th17 cells 
[90]. In the absence of such induced Tregs, Th2-immunity to helminths is improved 
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but pathology associated with type-2 inflammation is exacerbated. Thus, the 
plasticity of this lineage allows the microbiota to balance appropriate immune 
responses at mucosal surfaces [90]. Reciprocally, Th2 responses elicited by enteric 
N. brasiliensis infection  were found to reduce abundance of SFB, which have been 
implicated in the induction of pathological Th17 responses in inflammatory disorders 
[91].  
 
The fundamental interdependence of this co-evolution is illustrated by the ability of 
intestinal helminths to detect commensal bacterial cues that inform them that they 
have reached an appropriate microenvironment for their development where in turn, 
they can promote expansion of bacteria that induce regulatory responses to foster 
their survival [6, 92].  Much of the interest in helminth-endemic regions to date has 
focused on the interactions between GI-tract located worms and the bacterial 
microbiome, concentrating on T. trichiura but with inconsistent results, either 
indicating no effect or enrichment of bacterial diversity in infected children [18]. 
However, in experimental animal models, worm infections appear generally to be 
associated with a decrease in bacterial diversity [93]. Nevertheless, cross-sectional 
analysis of persistent infection with the related T. muris was associated with 
enrichment of Lactobacillus that was accompanied by a shift from regulatory to 
inflammatory immune responses [94]. By contrast, a more longitudinal analysis 
showed that T. muris infection mainly modulated Bacteroidetes, in particular by 
reducing diversity and abundance of Prevotella and Parabacteroides species and 
that such perturbation of the microbiota was transitory, essentially returning to 
normal upon clearance of the parasite [93, 95]. However, not all key immune system 
cell populations associated with chronic T. muris infection recovered [95], suggesting 
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that whilst perturbation of the microbiota due to helminth infection is reversible, some 
immunoregulatory networks appeared more stably modulated with implications for 
future pathophysiology.   
 
Reflecting this, as with other immunomodulatory interventions, helminth therapy has 
the potential for compromising immune responses to infections as evidenced, for 
example, by the impaired anti-viral immunity to murine norovirus resulting from 
experimental enteric coinfection with Trichinella spiralis.  Although this co-infection 
impacted on the wider macrobiome, helminth-induced impairment of antiviral 
immunity was evident in GF mice, seemingly as a result of the induction of AAMs 
[96]. Moreover, acute helminth infection with H. polygyrus or S. mansoni resulted in 
Th2-driven, IL-4/STAT6-mediated reactivation of murine gamma-herpes virus 
infection in vivo [97].  By contrast, enteric infection with H. polygyrus was found to 
reduce viral load and lung inflammation following respiratory syncytial virus (RSV) 
infection in a mouse model by induction of a microbiota-dependent type I IFN 
response in both the duodenum and the lungs [98].  
 
Dysbiosis of the microbiome has been implicated in the pathogenesis of a wide 
range of allergic and autoimmune inflammatory diseases as well as in metabolic 
syndrome and ageing [6, 99, 100]. Thus, investigation is underway to determine 
whether the protective actions of worms are direct and/or involve perturbation of 
microbiome-driven immunregulatory networks. Early studies focusing on GI helminth 
modulation of IBD [9, 101] showed that infection with H. polygyrus induced a type 2 
response and drove changes in the composition of the microbiota (reduced 
Bacteroides vulgatus burden and expansion of Clostridiales) that protected mice 
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from disease [6, 102].  Validating the relevance of these findings, individuals from 
endemic areas exhibited a similar protective microbiota that was reversed on 
deworming [103]. Interestingly from a therapeutic standpoint, analysis of patients 
with stable coeliac disease exposed to escalating doses of gluten showed that 
protection exhibited by those experimentally infected with hookworm was associated 
with an increasing enrichment of bacterial diversity over the course of the trial [104], 
specifically with respect to an increased abundance of Bacteroides species at the 
site of helminth infection in the duodenum [17]. 
 
With respect to interactions at other sites, which can harbour their own microbiota, a 
recent report showed that helminth infection and commensal bacteria interact to 
induce non-canonical regulatory T cells that act to maintain skin barrier function in 
the context of repeated challenge by pathogens [105], findings with potentially 
important implications for skin pathologies [106].  Most strikingly, however, the ability 
of H. polygyrus to ameliorate allergic asthma was abolished in mice treated with 
antibiotics. Chronic infection with the helminth resulted in increased abundance of 
gut Clostridiales species and consequently enhanced short-chain fatty acid 
production, both locally and systemically, that was responsible for the helminth-
induced regulatory T cell activity that conferred protection. Indeed, transfer of the 
worm-modified microbiota was sufficient to mimic the protection against allergic 
asthma. Similar effects were observed in pigs infected with Ascaris suum and 
humans with N. americanus, indicating a conserved immunoregulatory network 
[107].  
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Finally, and reminiscent of studies showing that microbial and metabolic alterations 
in early infancy affect risk of childhood asthma [108], an emerging area of interest is 
how helminth infection might modulate the gut-brain axis and consequently brain 
development during pregnancy, a dynamic period for the macrobiome [2, 109 ]. 
Impact on the macrobiota could potentially underpin the beneficial effects associated 
with helminth infection in neuroinflammatory and cognitive disorders, like autism 
[110].  
 
Concluding Remarks and Future Perspectives 
To date, trials of helminth therapies have generally proved disappointing [9, 111]: the 
reasons for this are not clear but presumably reflect a complicated mix of factors 
(e.g. age, gender, diet, health and infection history, exercise, environment, 
inappropriate helminth species and site of parasitism) that impact on the interplay 
between the immune system and the macrobiome. Nevertheless, the potential of the 
approach has generated enormous interest in the immunomodulatory agents 
secreted by the parasites [20] that may allow more targeted therapies tailored for 
particular actions and (treatment of) disorders, rather than the use of helminths per 
se.  Similarly, interest has also begun to focus on the potential of helminth and/or 
helminth product-conditioned effector cell transfer [112], the use of recombinant 
antigens as a new class of biologics [20, 111] or faecal macrobiota transplantation 
(FMT) from helminth-treated animals as evidenced by the ability of such FMT to 
mimic the protection against asthma afforded by live infection [107]. Finally, there is 
scope for more conventional drug discovery directed at targets identified by helminth 
action or mimicking the active moieties of helminth ES products. For example, small 
molecule analogues (SMAs) of the active phosphorylcholine-moiety of ES-62 exhibit 
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(differential) efficacy in a range of models of allergic and autoimmune inflammatory 
disorders [54, 113-115] that might lead to the generation of combination drug 
therapies aimed at targeting particular defects in immunoregulation underpinning the 
lifestyle and age-associated comorbidities currently plaguing our societies.  
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Figure 1. Helminths and their excreted/secreted (ES) products reset MyD88-
dependent inflammatory and mTOR-regulated metabolic pathways. 
Dysregulation of these pathways may generate triggers for the development of 
allergic and autoimmune disorders and metabolic syndrome, important comorbidities 
of ageing.  Helminth-based therapies can potentially normalise aberrant signaling 
(represented in red) and/or induce counter-regulatory pathways (represented in blue) 
to restore homeostatic regulation of this network. This can be achieved by resetting 
the balance of effector:regulatory B and T cells, M1:M2 macrophages and their 
cytokines and immunoregulatory products to resolve inflammation and promote 
tissue repair.  
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Figure 2. Helminths exhibit therapeutic potential in inflammatory disease by 
targeting integrated inflammatory and stromal cell networks. Helminths can 
interact with a range of innate and adaptive immune system cells to disrupt 
pathogenic regulatory networks promoted by stromal cells in particular 
microenvironmental niches: protective responses (blue arrows) promoted and 
pathogenic mediators (red arrows) suppressed (blue crosses) by helminths to effect 
immunoregulation are shown.  
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Trends Box  
The rapid eradication of parasitic worms in the last 50 years has been shadowed by 
the rise in allergy, autoimmunity and more recently, by their reciprocal risk factor, 
obesity in the industrialised and developing worlds 
• Consideration of the Hygiene Hypothesis has identified that eradication of worms 
may have left an unbalanced, hyperactive immune system and suggested the 
therapeutic potential of parasitic worms in inflammatory disease 
• Clinical trials employing live worms to date have generally proved somewhat 
disappointing and so the focus has shifted to exploitation of individual worm-
derived immunomodulators as therapeutics or consideration of developing drugs 
based on their structure and/or targets of action 
• Exciting recent advances in our understanding of how worms subvert immune 
responses have highlighted potential new therapeutic targets for exploration  
• The range of diseases for which helminths have therapeutic potential now 
extends from allergy and autoimmunity to cardiovascular disease, metabolic 
syndrome and autism  
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Box 1. Useful helminth ES products 
The disappointing outcome of worm therapy trials allied to reservations about 
interventions using live pathogens has generated intense focus on identifying and 
characterising the ES molecules produced by helminths (secretome) as a first step to 
producing a new class of “biologics” with evolutionarily selected safety profiles 
(reviewed in [22-24, 116, 117]). As an example, ES-62, a phosphorylcholine (PC)-
containing glycoprotein secreted by Acanthocheilonema viteae is amongst the best 
characterised of helminth ES products and has demonstrated therapeutic promise in 
certain allergic and autoimmune conditions (reviewed in [22, 24-26]). However, the 
advent of more sensitive technologies allowing characterization of expressed 
sequence tags and of late, proteomic analysis has identified large numbers of ES 
from an ever-increasing range of parasitic helminth species [23, 118] and, in the 
case of Brugia malayi, the secretome has been evaluated at different parasite stages 
[23, 119-121]. 
 
Currently, there is much interest in exploiting ES to treat autoimmune and allergic 
disease by the therapeutic transfer of “conditioned” myeloid cells (reviewed [112]): 
the potential of this approach is evidenced in animal models by the ability of DCs 
exposed to F. hepatica total extract to suppress CIA [122] or in the case of 
Trichinella spiralis- or Hymenolepis diminuta antigen, experimental allergic 
encephalomyelitis (EAE) [123] and colitis, respectively [124]. Likewise, the 
generation of AAM-like macrophages by A. viteae cystatin also indicates their 
potential in treatment of allergic airway inflammation and experimental colitis [112, 
125]. 
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Notably, not all ES-products are proteins. Rather they comprise a wide range of 
biologically active molecules including glycans [20] and microRNAs [20, 21, 126, 
127] as well as small molecule metabolites, exemplified by the immunoregulatory 
actions of fluke peptides, eicosanoids (Schistosoma mansoni), ascaroside lipids and 
short chain fatty acids (SCFA) generated by Toxocara canis, Ostertagia circumcincta 
and Haemonchus contortus [20]. Although many of these agents are released in 
free-form, the discovery of helminth-derived exosomes/extracellular vesicles 
containing varied cargo mixes [21, 126-128] has generated much interest in their 
function. Those containing immunoregulatory microRNAs have been identified from 
Fasciola hepatica, Heligomosomides polygyrus, Litomosoides sigmodontis, 
Dicrocoelieum dendriticum and Dirofilaria immitis, which following dissection of their 
roles could be exploited therapeutically [21].   
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Outstanding Questions Box  
How can we exploit the emerging new concepts in helminth immunomodulation to 
inform on development of the immune response and pathogenesis in 
inflammatory-based disease and consequently, to design novel, safe 
immunotherapies? In particular:  
• how do parasitic worms and their ES products harness host homeostatic 
mechanisms to reset the effector:regulatory balance (Tregs:Teffs; 
Bregs:Beffs; M1:M2 macrophages) and limit/resolve inflammation and 
promote tissue repair e.g. by stimulating autophagy? 
• what are the helminth-induced changes in the epigenetic landscape of 
progenitor and/or effector cells that result in “training” of host immune 
responses?  
• can we mimic helminth-mediated modulation of  host metabolomics to reset 
immunophenotypes (e.g. Th subsets and memory responses) and 
inflammation (glycolytic and oxidative phosphorylation metabolism)? 
• how can we therapeutically reproduce the effects of helminths on 
macrobiome/host metabolome to subvert inflammation and protect against 
disease? 
• does chronic infection, particularly during pregnancy, have beneficial 
transgenerational (epigenetic/macrobiome) effects? 
 
Why is lack of protection against inflammatory disease the most frequent 
outcome of clinical trials with live infections? In particular: 
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• what is the impact of the macrobiome, co-infections and differential 
inflammatory microenvironments on both parasite infection and target 
pathological disorder? 
• what are the best helminth-based therapies -  worm-derived biologics, 
conditioned cell transfer or drugs designed to mimic their active moieties or 
mode of action or alternatively, (probiotic) dietary supplements?  
 
Do we need to reconsider our programs of mass eradication/vaccination against 
parasitic helminths in the developing world? 
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